Senate Candidate John Braun’s Financial Backing and Legislative Record Under Scrutiny
State Senator John Braun, a Republican from Washington, is facing increased scrutiny as he campaigns for the U.S. House of Representatives in the 3rd District, a seat presently held by Democrat Marie Gluesenkamp Perez. Central to the criticism are Braun’s financial ties to the pharmaceutical and health insurance industries coupled with his legislative history.
Over his political career since 2012, Braun has amassed $73,550 in donations from pharmaceutical companies and $37,400 from the health insurance sector. These contributions account for approximately 10% of all donations received by Braun.
In 2022, Braun was a vocal opponent of a bipartisan initiative aimed at establishing the Prescription Drug Affordability Board in Washington. This board’s mandate is to assess medication costs and potentially cap payments by individuals, state agencies, and insurers. Despite support from groups like the AARP, which emphasized the board’s potential to “lead to lower insurance premiums, reduce taxpayer spending on health care, and would help ensure people can afford the medication they need,” Braun’s stance aligned with industry interests.
The Pharmaceutical Research and Manufacturers of America (PhRMA), a major trade group that contributed to Braun’s campaigns in 2015 and 2016, has been critical of such affordability boards.
The disagreement extended back to 2021 when Braun opposed a legislative effort to allow Washington state to produce and distribute generic versions of popular drugs, which would be less expensive alternatives to brand-name medications. In 2020, he resisted a proposal for the state to bulk-purchase insulin for patients at a reduced rate. Similarly, Braun opposed a requirement for health insurers to cover pre-existing conditions.
Despite these positions, Braun maintains that cost reduction remains at the forefront of his agenda. He criticized his opponent, Gluesenkamp Perez, for her opposition to what he described as “the largest tax cut in history,” although the cut is characterized by its disproportionate advantage to the wealthy, offset by a $1 trillion reduction in Medicaid funding.
Health care affordability is anticipated to be a pivotal issue in the forthcoming 2026 electoral race. According to a June 2026 Gallup poll, the ability of Americans to afford health care has reached a five-year low, highlighting the significance of this topic.
Adding a layer to Braun’s campaign is his endorsement from former President Donald Trump, which further cements his profile within the Republican Party.
The post Braun took drug industry money, opposed lower health care costs appeared first on American Journal News.
